Your browser doesn't support javascript.
loading
Clinicoradiological and neuropathological evaluation of primary progressive aphasia.
Shir, Dror; Corriveau-Lecavalier, Nick; Bermudez Noguera, Camilo; Barnard, Leland; Pham, Nha Trang Thu; Botha, Hugo; Duffy, Joseph R; Clark, Heather M; Utianski, Rene L; Knopman, David S; Petersen, Ronald C; Boeve, Bradley F; Murray, Melissa E; Nguyen, Aivi T; Reichard, R Ross; Dickson, Dennis W; Day, Gregory S; Kremers, Walter K; Graff-Radford, Neill R; Jones, David T; Machulda, Mary M; Fields, Julie A; Whitwell, Jennifer L; Josephs, Keith A; Graff-Radford, Jonathan.
Afiliación
  • Shir D; Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
  • Corriveau-Lecavalier N; Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
  • Bermudez Noguera C; Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
  • Barnard L; Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
  • Pham NTT; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
  • Botha H; Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
  • Duffy JR; Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
  • Clark HM; Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
  • Utianski RL; Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
  • Knopman DS; Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
  • Petersen RC; Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
  • Boeve BF; Department of Quantitative Health Sciences, Mayo Clinic Rochester, Rochester, Minnesota, USA.
  • Murray ME; Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
  • Nguyen AT; Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
  • Reichard RR; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
  • Dickson DW; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
  • Day GS; Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
  • Kremers WK; Department of Neurology, Mayo Clinic, Jacksonville, Florida, USA.
  • Graff-Radford NR; Department of Quantitative Health Sciences, Mayo Clinic Rochester, Rochester, Minnesota, USA.
  • Jones DT; Department of Neurology, Mayo Clinic, Jacksonville, Florida, USA.
  • Machulda MM; Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
  • Fields JA; Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota, USA.
  • Whitwell JL; Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota, USA.
  • Josephs KA; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
  • Graff-Radford J; Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
J Neurol Neurosurg Psychiatry ; 95(9): 812-821, 2024 Aug 16.
Article en En | MEDLINE | ID: mdl-38514176
ABSTRACT

BACKGROUND:

Primary progressive aphasia (PPA) defines a group of neurodegenerative disorders characterised by language decline. Three PPA variants correlate with distinct underlying pathologies semantic variant PPA (svPPA) with transactive response DNA-binding protein of 43 kD (TDP-43) proteinopathy, agrammatic variant PPA (agPPA) with tau deposition and logopenic variant PPA (lvPPA) with Alzheimer's disease (AD). Our objectives were to differentiate PPA variants using clinical and neuroimaging features, assess progression and evaluate structural MRI and a novel 18-F fluorodeoxyglucose positron emission tomography (FDG-PET) image decomposition machine learning algorithm for neuropathology prediction.

METHODS:

We analysed 82 autopsied patients diagnosed with PPA from 1998 to 2022. Clinical histories, language characteristics, neuropsychological results and brain imaging were reviewed. A machine learning framework using a k-nearest neighbours classifier assessed FDG-PET scans from 45 patients compared with a large reference database.

RESULTS:

PPA variant distribution 35 lvPPA (80% AD), 28 agPPA (89% tauopathy) and 18 svPPA (72% frontotemporal lobar degeneration-TAR DNA-binding protein (FTLD-TDP)). Apraxia of speech was associated with 4R-tauopathy in agPPA, while pure agrammatic PPA without apraxia was linked to 3R-tauopathy. Longitudinal data revealed language dysfunction remained the predominant deficit for patients with lvPPA, agPPA evolved to corticobasal or progressive supranuclear palsy syndrome (64%) and svPPA progressed to behavioural variant frontotemporal dementia (44%). agPPA-4R-tauopathy exhibited limited pre-supplementary motor area atrophy, lvPPA-AD displayed temporal atrophy extending to the superior temporal sulcus and svPPA-FTLD-TDP had severe temporal pole atrophy. The FDG-PET-based machine learning algorithm accurately predicted clinical diagnoses and underlying pathologies.

CONCLUSIONS:

Distinguishing 3R-taupathy and 4R-tauopathy in agPPA may rely on apraxia of speech presence. Additional linguistic and clinical features can aid neuropathology prediction. Our data-driven brain metabolism decomposition approach effectively predicts underlying neuropathology.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Encéfalo / Imagen por Resonancia Magnética / Afasia Progresiva Primaria / Tomografía de Emisión de Positrones Límite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Neurol Neurosurg Psychiatry Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Encéfalo / Imagen por Resonancia Magnética / Afasia Progresiva Primaria / Tomografía de Emisión de Positrones Límite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Neurol Neurosurg Psychiatry Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos